FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus and Other Infectious Diseases.”
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that its research partner Mannin Research Inc. is developing new therapeutics to treat a variety of vascular diseases, including the new coronavirus which originated in Wuhan, China, with a rapidly rising number of deaths and confirmed cases. Coronavirus has been declared a Global Health Emergency by the World Health Organization (WHO).
Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need.
Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi and parasites, and can be transmitted by direct or indirect contact. Globally, infectious diseases such as malaria, HIV, tuberculosis, influenza, hepatitis A, hepatitis C and recently the novel (new) coronavirus (named “2019-nCoV”) put major strains on public health. However, infectious disease therapeutics are used to constrain the growth of these diseases, as these drugs can act through the host’s defense system and directly target the malicious pathogen. Overall, the growth of this market is influenced by various major factors, such as the increasing occurrence of infectious diseases, the growing use of direct-acting anti-viral, growing healthcare awareness, increasing government funding in developing countries and a growing geriatric population. In addition, the public is now more aware of symptoms associated with various diseases than ever before, aiding early diagnosis rates among individuals and providing growth opportunities for the market. And, in 2019, the Global Infectious Disease Therapeutics Market size was worth USD 105.13 Billion; it is now estimated to reach USD 154.18 Billion by the end of 2024, while a growing potential of 7.96 % during the forecast period 2019 – 2024, according to Market Data Forecast.
Among the avalanche of information concerning the recent outbreak of the 2019-nCoV, is the morsel from January 30th, 2020: The International Health Regulations Emergency Committee of the World Health Organization agreed that the outbreak now meets the criteria for a Public Health Emergency of International Concern. Representatives of the Ministry of Health of the People’s Republic of China reported on the current situation – as of late last week, there were 7,711 confirmed and 12,167 suspected cases throughout the country. Of the confirmed cases, 1370 are severe and 170 people have died. 124 people have recovered and been discharged from hospital. Meanwhile, in the United States, the CDC has announced that it is closely monitoring an outbreak of respiratory illness caused by the novel coronavirus, and that the first instance of person-to-person spread with this virus has been confirmed in the U.S on January 30th, 2020. Coronaviruses are a large family of viruses that are common in many different species of animals, including camels, cattle, cats, and bats. However, it is only rarely that animal coronaviruses can infect people and subsequently spread throughout the population, but such a list includes MERS, SARS, and now the 2019-nCoV.
For more information, please visit: Q BioMed Inc.
For more corporate news on Q BioMed Inc., check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.